Category:
Health Services
Protein Design and Engineering Market | Market Size | Industry Analysis | 2035 Post the marketing of Vitravene®, the first antisense oligonucleotide-based therapy to receive approval (in 1998), various stakeholders have undertaken multiple research initiatives to verify the potential of oligonucleotides as therapeutic agents




